|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
By contrast MAP3K15 (ASK3) may protect from hypertension and BRAF inhibitors in clinical use may induced acute kidney injury and nephrotic syndrome.
|
31196660 |
2020 |
|
Kidney Failure, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
By contrast MAP3K15 (ASK3) may protect from hypertension and BRAF inhibitors in clinical use may induced acute kidney injury and nephrotic syndrome.
|
31196660 |
2020 |
|
Skin Manifestations
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Patients from this cohort were screened for cutaneous manifestations, and BRAF c.1799T>A (p.V600E) mutational analysis was conducted in novel skin manifestations.
|
31120137 |
2020 |
|
Endosalpingiosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The proliferative activity as assessed by Ki-67 immunohistochemistry was lower in endosalpingiosis than in low-grade serous tumours, and endosalpingiosis with either a BRAF or KRAS mutation had a significantly lower Ki-67 index than those without.
|
31576556 |
2020 |
|
Adenocarcinoma of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
Patients with pancreatic adenocarcinoma and BRAF-mutant colorectal cancer (CRC) were enrolled in the expansion stage.
|
31848189 |
2020 |
|
Blastoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Screening of RAS (Kirsten rat sarcoma viral oncogene homolog (KRAS), neuro-blastoma RAS viral oncogene homolog (NRAS), and v-raf murine sarcoma viral oncogene homolog B1 (BRAF)) somatic mutations is necessary prior to considering anti-epidermal growth factor receptor (EGFR) therapies in CRC patients.
|
31475312 |
2020 |
|
Adult Gliosarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The coexistence of gliosarcoma and arteriovenous malformation with the BRAF V600E mutation: case report.
|
31759151 |
2020 |
|
Sialadenoma papilliferum
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E and AKT1 E17K in SP and IPMN) would be useful for the correct diagnosis of minor salivary gland papillary-cystic tumours.
|
31505033 |
2020 |
|
Childhood Gliosarcoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The coexistence of gliosarcoma and arteriovenous malformation with the BRAF V600E mutation: case report.
|
31759151 |
2020 |
|
anaphylaxis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We report a case of anaphylactic reaction to the BRAF inhibitor dabrafenib administered as a first-line treatment.
|
30383722 |
2019 |
|
Developmental Disabilities
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Cardiofaciocutaneous syndrome (CFCS) is a rare developmental disorder that is phenotypically similar to Noonan syndrome and is associated with mutations in BRAF, MEK1, MEK2, and KRAS.
|
31125963 |
2019 |
|
Disseminated Intravascular Coagulation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein, we describe the first case of disseminated intravascular coagulation occurring in BRAF and NRAS-mutant metastatic melanoma, and systematically review the literature regarding disseminated intravascular coagulation in melanoma.
|
31095038 |
2019 |
|
Ependymoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The p.Val600Glu was found in 14/75 grade II GG.No EP were BRAF mutated.
|
31673897 |
2019 |
|
Factor X Deficiency
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We report on a 3-year-old child with recurrent, metastatic (bone) BRAF mutation-positive melanoma.He also had severe factor X deficiency.
|
30376464 |
2019 |
|
Genital Neoplasms, Female
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Papilloma of the Fallopian Tube: A Rare Gynecologic Neoplasm Harboring a BRAF (c.1799T>A) Mutation (V600E).
|
29851866 |
2019 |
|
Glycogen Storage Disease Type VI
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutation of BRAF (V600E) was reported by 1st NGS and oral vemurafenib stabilized her disease for 6 months.
|
30462564 |
2019 |
|
Head and Neck Neoplasms
|
0.010 |
GeneticVariation
|
group |
BEFREE |
<b>Background:</b> Ameloblastoma is a rare head and neck tumor characterized by a high incidence of BRAF mutation providing a rationale for the use of BRAF inhibitors in patients with advanced disease.
|
31781502 |
2019 |
|
Hodgkin Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A total thyroidectomy with bilateral lymph node dissection was performed and the microscopic examination revealed a 2-cm PTC with BRAF mutation and HL (mixed cellularity) in the bilateral lymph nodes.
|
30653166 |
2019 |
|
Hyponatremia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our hypothesis is that BRAF/MEK inhibitors lead to hyponatremia and water retention (so-called dilution hyponatremia) by activating aquaporin 2 (AQP2) trafficking from its intracellular compartment to the luminal cell membrane, and by activating ENaC channel.
|
30387922 |
2019 |
|
Oral Manifestations
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We report on a rare case of its primary oral manifestation that was treated successfully with the BRAF-specific agent, vemurafenib, after insufficient standard LCH treatment.
|
31666812 |
2019 |
|
Paraganglioma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Absence of BRAF mutation in pheochromocytoma and paraganglioma.
|
28043156 |
2019 |
|
Sarcoidosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Cancer-targeted therapies such as BRAF or MEK inhibitors were associated with sarcoidosis reactions in 37 cases.
|
31612562 |
2019 |
|
Ki-1+ Anaplastic Large Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation.
|
30320628 |
2019 |
|
Adult Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A total thyroidectomy with bilateral lymph node dissection was performed and the microscopic examination revealed a 2-cm PTC with BRAF mutation and HL (mixed cellularity) in the bilateral lymph nodes.
|
30653166 |
2019 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A total thyroidectomy with bilateral lymph node dissection was performed and the microscopic examination revealed a 2-cm PTC with BRAF mutation and HL (mixed cellularity) in the bilateral lymph nodes.
|
30653166 |
2019 |